Public Release: 

Keystone Symposia and Cancer Research UK announce multi-year collaboration

Keystone Symposia on Molecular & Cellular Biology

SILVERTHORNE, COLORADO, USA - September 24, 2018 -

Keystone Symposia and Cancer Research UK are pleased to announce their new collaboration consisting of a series of annual cancer-related scientific research conferences organized by Keystone Symposia in collaboration with Cancer Research UK. The events will be held in various locations globally.

In 2019, the following six conferences will take place as part of the inaugural series: DNA Replication and Genome Instability, January 13-17, 2019 in Snowbird, Utah, USA; Cancer Vaccines, January 20-24, 2019 in Vancouver, British Columbia, Canada; Tumor Metabolism, February 24-28, 2019 in Keystone, Colorado, USA; Uncovering Mechanisms of Immune-Based Therapy in Cancer and Autoimmunity, February 18-22, 2019 in Breckenridge, Colorado, USA; and Cancer Metastasis: The Role of Metabolism, Immunity and the Microenvironment, March 15-19, 2019 in Florence, Italy.

Cancer Research UK-funded cancer experts contribute to the program development process and play lead roles in putting together the scientific programs of each of the conferences.

In addition, Cancer Research UK is funding 10 scholarships for junior investigators - i.e., graduate students and postdoctoral fellows/associates - to attend these conferences. Eligible candidates must submit an abstract and apply through the regular Keystone Symposia scholarship process; the application deadlines precede the conferences by approximately four months. The application deadlines are October 4 and October 2, respectively, for the first two conferences on DNA Replication and Recombination and Cancer Vaccines.

According to Dr. Karen Vousden, Chief Scientist at Cancer Research UK and Group Leader at the Francis Crick Institute, "We're delighted to be teaming up with Keystone Symposia to co-host a series of cancer conferences and offer travel scholarships to students and postdocs. Together, we're supporting dialogue at the leading edge of cancer research and enabling researchers from around the world to build connections."

Dr. Jane L. Peterson, Keystone Symposia's President and CEO, added: "Keystone Symposia is delighted to partner with Cancer Research UK on cancer research conferences worldwide. Their invaluable support will allow us to offer an expanding array of conferences on cancer vaccines, immunotherapy and other important and cutting-edge topics that hold great promise for increasing our understanding of cancer and other diseases, and accelerating the development of more effective therapies."


About Keystone Symposia on Molecular and Cellular Biology

Keystone Symposia on Molecular and Cellular Biology, a 501(c)(3) nonprofit organization, has been conducting internationally renowned, open scientific conferences since its founding as UCLA Symposia in 1972 and has been headquartered in Summit County, Colorado, USA since 1990.

Keystone Symposia will convene 59 face-to-face conferences in the 2018-2019 season, the majority of which take place between January and April 2019, on topics ranging from cancer and immunology to neuroscience and genomics. Registration fees are supplemented by generous financial support from corporate, foundation and individual donors as well as government grants.

From 2016 to 2018, the organization marked a special two-year period of "Celebrating Diversity" and is pleased to report that during this period, representation by invited female speakers at the podium increased from 28% to 33% of overall speakers across the Keystone Symposia conference portfolio, while representation of UR invited speakers increased from approximately 3% to 5%.

More information about the organization and its cancer conferences is located at and, respectively.

About Cancer Research UK

Cancer Research UK (CRUK) is the largest independent funder of cancer research in Europe, and the world's leading charity dedicated to cancer research. Our vision is to bring forward the day when all cancers are cured. We fund high-caliber, innovative research that we believe has the potential to provide the greatest benefit to the public and cancer patients.

Our diverse portfolio spans a breadth of research areas, from fundamental discovery research to understand the biology and causes of cancer, through translational research to bring the latest discoveries to the benefit of patients, to drug discovery to identify potential new treatments, clinical research to deliver the best treatments for patients, and population-level research covering epidemiology, prevention and early detection of cancer.

We are proud to support 4,000 researchers, doctors and nurses in institutions across the UK and internationally. Our progress is dependent on these outstanding individuals and teams conducting high-quality research.

We support over 250 clinical trials, with more than 22,000 people joining our trials each year. We work in partnership to achieve the greatest impact. We are the gateway through which researchers and institutions can join forces with academic collaborators and commercial partners. Our open, collaborative research community expands the bounds of what research teams can achieve individually, and our established industry links and proven commercialization experience enable us to develop new ideas to their full potential.

More information can be found out

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.